CST1-Guided Oral Glucocorticoids Management for CRSwNP (COMPASS)
Efficacy of CST1-Guided Oral Glucocorticoid Therapy for Chronic Rhinosinusitis With Polyps
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100000
- Beijing Tongren Hospital, Capital Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-70 years old;
- All meet the diagnostic criteria of CRSwNP in EPOS2020;
- Investigator-assessed endoscopic bilateral Nasal Polyp Size Score (NPSS) was greater than or equal to 4 (minimum score of 2 per nasal cavity);
- Patients with asthma were in a stable state, with FEV1 > 50% of the predicted value or 50% of the optimal value of personal FEV1; (5) Good compliance, able to complete clinical observation.
Exclusion Criteria:
- Medication history of oral glucocorticoids within 3 months before enrollment, antibiotics within 2 weeks;
- Oral glucocorticoid contraindications, such as diabetes, femoral head necrosis, gastric ulcer, etc.;
- Any nasal and/or sinus surgery within 3 months before enrollment;
- Patients have conditions or comorbidities that may preclude evaluation of the primary efficacy endpoint, such as: unilateral posterior nasal polyp of maxillary sinus, acute rhinitis, nasal infection or upper respiratory tract at the screening period or within 2 weeks before the screening period infection, acute asthma attack within 4 weeks, current drug-induced rhinitis, allergic fungal sinusitis (AFRS), benign or malignant tumor of nasal cavity;
- Important clinical comorbidities that may interfere with clinical effectiveness, including but not limited to: active upper or lower respiratory tract infection, cystic fibrosis, eosinophilic granuloma with polyvasculitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener's granulomatosis), Young's syndrome, etc.;
- Accompanying serious diseases or recurrent chronic diseases with poor systemic control, such as (but not limited to), active infection, cardiovascular disease, tuberculosis or other pathogen infection, diabetes, autoimmune disease, HIV, hepatitis B, Hepatitis C or parasitic diseases, malignant tumors, etc.;
- Subjects with severe liver and kidney function injury; such as, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >2 times the upper limit of normal, serum creatinine > the upper limit of normal value;
- Known or suspected immunosuppression, including a history of invasive opportunistic infections (such as tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pulmonary cysts, aspergillosis), even if the infection has subsided;
- Women who were pregnant or planned to become pregnant during the study, or who were breastfeeding;
- Subjects who were fertile but were reluctant to use medically approved and effective contraception;
- Those with a history of alcohol or drug abuse;
- Those who believed the patient had other medical or non-medical conditions that were not suitable for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Oral Glucocorticoids group
Intervention Period:oral glucocorticoids(methylprednisolone 24mg qd, 2-week duration)+nasal spray (Budesonide Nasal Spray 64ug per Nostril, bid, 2-week duration) follow-up period:nasal spray(Budesonide Nasal Spray 64ug per Nostril, bid, 24-week duration)
|
methylprednisolone 24mg qd, 2-week duration
Other Names:
|
|
Placebo Comparator: Placebo group
Intervention Period:oral placebo+nasal spray(oral placebo 24mg qd, 2-week duration)+nasal spray (Budesonide Nasal Spray 64ug per Nostril, bid, 2-week duration) follow-up period:nasal spray(Budesonide Nasal Spray 64ug per Nostril, bid, 24-week duration)
|
oral placebo 24mg qd, 2-week duration
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The change in endoscopic polyp score
Time Frame: Baseline, week 2, week 6, week 10, week 14, week 18, week 22, week 26
|
Bilateral polyp volume size described using the Nasal Polyp Size Score (NPSS) score.
(0 - 4 points per side: 0 = no polyp; 1 = small polyp in the middle meatus, not reaching the inferior border of the middle turbinate; 2 = small polyp in the middle meatus, reaching the inferior border of the middle turbinate; 3 = large polyp protruding from the middle meatus, not reaching the inferior border of the inferior turbinate; 4 = large polyp that almost causes most or complete obstruction of the nasal cavity.)
|
Baseline, week 2, week 6, week 10, week 14, week 18, week 22, week 26
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The change in Total Nasal Symptom Score(TNSS)
Time Frame: Baseline, week 2, week 6, week 10, week 14, week 18, week 22, week 26
|
Total Nasal Symptom Score was are graded on a 3-point scale.
(0= no symptoms; 1= mild symptoms; 2= moderate symptoms; 3= severe symptoms).
|
Baseline, week 2, week 6, week 10, week 14, week 18, week 22, week 26
|
|
The change in SNOT-22 score
Time Frame: Baseline, week 2, week 6, week 10, week 14, week 18, week 22, week 26
|
The 22-item Sino-nasal outcome test (SNOT-22) was used to evaluate the changes in symptoms of patients.
According to the severity of symptoms caused by RCRS, each item was divided into 6 levels: no distress (0 points), mild distress (1 point), mild distress (2 points) ), moderate distress (3 points), severe distress (4 points), very severe distress (5 points).
The higher the score, the more severe the symptoms, and the final total score of the item is counted.
|
Baseline, week 2, week 6, week 10, week 14, week 18, week 22, week 26
|
|
The change in asthma ACQ Score
Time Frame: Baseline, week 2, week 6, week 10, week 14, week 18, week 22, week 26
|
For patients with asthma, we assessed the change of asthma symptoms through the Asthma Control Questionnaire(ACQ).
Each question was scored on a scale of 0 to 6 according to the severity.
The result score of each item was averaged.
A score of <0.75 indicated that the asthma had been completely controlled; a score of 0.75-1.5 indicates well-controlled asthma; a score of >1.5 indicates that asthma is not controlled.
|
Baseline, week 2, week 6, week 10, week 14, week 18, week 22, week 26
|
|
The change of CST1
Time Frame: Baseline, week 2, week 6, week 10, week 14, week 18, week 22, week 26
|
The change of Cystatin 1
|
Baseline, week 2, week 6, week 10, week 14, week 18, week 22, week 26
|
|
The change of biomarker
Time Frame: Baseline, week 2, week 6, week 10, week 14, week 18, week 22, week 26
|
Changes in expression levels of biomarker in nasal brush exfoliated cells, nasal secretions and nasal microbes.
|
Baseline, week 2, week 6, week 10, week 14, week 18, week 22, week 26
|
|
The change in AE / SAE recording
Time Frame: Baseline, week 2, week 6, week 10, week 14, week 18, week 22, week 26
|
Any adverse event
|
Baseline, week 2, week 6, week 10, week 14, week 18, week 22, week 26
|
|
The needs of upgrading treatment
Time Frame: Baseline, week 2, week 6, week 10, week 14, week 18, week 22, week 26
|
The needs of upgrading treatment includes surgery, oral glucocorticoids or monoclonal antibodies treatment.
|
Baseline, week 2, week 6, week 10, week 14, week 18, week 22, week 26
|
|
The change of inflammatory cell
Time Frame: Baseline, week 2, week 26
|
The change of inflammatory cell in nasal polyps
|
Baseline, week 2, week 26
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Otorhinolaryngologic Diseases
- Pathological Conditions, Anatomical
- Nose Diseases
- Nasal Polyps
- Polyps
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antiemetics
- Gastrointestinal Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Neuroprotective Agents
- Protective Agents
- Methylprednisolone
- Glucocorticoids
Other Study ID Numbers
Other Study ID Numbers
- TR-COMPASS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.